Johnson & Johnson Q4 Adjusted EPS $2.29 Beats $2.28 Estimate, Sales $21.39B Beat $20.99B Estimate
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson (NYSE:JNJ) exceeded Q4 earnings and sales estimates with an EPS of $2.29, surpassing the $2.28 forecast, and reported sales of $21.39B, beating the $20.99B estimate. This reflects an 11.71% increase in EPS from last year, despite a 9.75% decrease in sales from the same period.
January 23, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson reported a strong Q4 with EPS and sales beating estimates, indicating robust financial performance despite a year-over-year sales decline.
Beating both EPS and sales estimates typically generates positive investor sentiment, which can lead to a short-term increase in stock price. The reported growth in EPS year-over-year is particularly encouraging, although the decrease in sales may temper some of the positive impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100